This brand name is authorized in Canada, United States
The drug PROGLYCEM contains one active pharmaceutical ingredient (API):
|
1
Diazoxide
UNII O5CB12L4FN - DIAZOXIDE
|
|
Diazoxide is a peripheral vasodilator and has qualitatively the same effect on blood vessels as benzothiazine compounds, but the effect is more rapid and profound. Unlike benzothiazines, diazoxide is non-diuretic and causes retention of sodium and water. It causes a prompt increase in blood glucose by a direct inhibitory action on the secretion of insulin by the beta cells in the Islets of Langerhans. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C02DA01 | Diazoxide | C Cardiovascular system → C02 Antihypertensives → C02D Arteriolar smooth muscle, agents acting on → C02DA Thiazide derivatives |
| V03AH01 | Diazoxide | V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AH Drugs for treatment of hypoglycemia |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: CA | Health Products and Food Branch | Identifier(s): 00503347 |
| Country: US | FDA, National Drug Code | Identifier(s): 0575-6200 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
